Amarantus Bioscience Holdings Inc (AMBS) financial statements (2020 and earlier)

Company profile

Business Address 655 MONTGOMERY STREET
SAN FRANCISCO, CA 94111
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

3/31/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 0010
Cash and cash equivalents 0010
Prepaid expense and other current assets1
Other undisclosed current assets 100 
Total current assets: 1011
Noncurrent Assets
Property, plant and equipment 00  
Intangible assets, net (including goodwill), including: 311
Goodwill 8   
Intangible assets, net (excluding goodwill) 311 
Other undisclosed intangible assets, net (including goodwill) (8) 
Other undisclosed noncurrent assets 80 1
Total noncurrent assets: 11211
TOTAL ASSETS: 12221
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 8413
Accounts payable  313
Accrued liabilities  00 
Interest and dividends payable 00  
Other undisclosed accounts payable and accrued liabilities 8   
Debt 1 11
Derivative instruments and hedges, liabilities 5 60
Due to related parties 0000
Other undisclosed current liabilities 2301
Total current liabilities: 16695
Noncurrent Liabilities
Other undisclosed noncurrent liabilities 1   
Total noncurrent liabilities: 1   
Total liabilities: 17695
Temporary equity, carrying amount 3   
Stockholders' equity
Stockholders' equity attributable to parent, including: (9)(4)(8)(4)
Common stock 0110
Additional paid in capital 7545198
Accumulated deficit (92)(55)  
Other undisclosed stockholders' equity attributable to parent 95(27)(12)
Other undisclosed stockholders' equity   1 
Total stockholders' equity: (9)(4)(7)(4)
TOTAL LIABILITIES AND EQUITY: 12221

Income statement (P&L) ($ in millions)

3/31/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Operating expenses (25)(21)(6)(4)
Other operating expense, net
(Other Expenses)
  (0)  
Other undisclosed operating income (loss)  0 (1)
Operating loss: (25)(21)(6)(5)
Nonoperating income (expense) (0)(6)(9)0
Investment income, nonoperating 4000
Interest and debt expense (1)(2)(9) 
Loss from continuing operations before equity method investments, income taxes: (27)(29)(24)(5)
Other undisclosed income from continuing operations before income taxes 129 
Loss before gain (loss) on sale of properties: (25)(27)(15)(5)
Other undisclosed net income    1
Net loss: (25)(27)(15)(4)
Other undisclosed net income (loss) attributable to parent (0)0(0)(1)
Net loss attributable to parent: (25)(27)(15)(5)
Preferred stock dividends and other adjustments (4)(1)(0) 
Other undisclosed net loss available to common stockholders, basic (8)   
Net loss available to common stockholders, basic: (37)(28)(15)(5)
Convertible preferred dividends (8)   
Net loss available to common stockholders, diluted: (45)(28)(15)(5)

Comprehensive Income ($ in millions)

3/31/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss: (25)(27)(15)(4)
Comprehensive loss, net of tax, attributable to parent: (25)(27)(15)(4)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: